{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:55:06Z","timestamp":1778802906365,"version":"3.51.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CP19\/00098"],"award-info":[{"award-number":["CP19\/00098"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI20\/00505"],"award-info":[{"award-number":["PI20\/00505"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.dsx.2023.102788","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T17:34:30Z","timestamp":1685900070000},"page":"102788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors"],"prefix":"10.1016","volume":"17","author":[{"given":"Shaghayegh","family":"Khanmohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Ramos-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-6137","authenticated-orcid":false,"given":"Mohammad Shafi","family":"Kuchay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","article-title":"Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102788_bib2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","article-title":"Gut microbiome, liver immunology, and liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1515\/almed-2021-0009","article-title":"Biochemical assessment of metabolic associated fatty liver disease","volume":"2","author":"Guerra-Ruiz","year":"2021","journal-title":"Advances in Laboratory Medicine\/Avances en Medicina de Laboratorio."},{"key":"10.1016\/j.dsx.2023.102788_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41577-020-00473-z","article-title":"NOD-like receptor-mediated plant immunity: from structure to cell death","volume":"21","author":"Saur","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.dsx.2023.102788_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fimmu.2014.00327","article-title":"NOD-like receptors: master regulators of inflammation and cancer","volume":"5","author":"Saxena","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib8","first-page":"1","article-title":"New insights into Nod-like receptors (NLRs) in liver diseases","volume":"10","author":"Xu","year":"2018","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102788_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2010.04.026","article-title":"Hepatocytes express functional NOD1 and NOD2 receptors: a role for NOD1 in hepatocyte CC and CXC chemokine production","volume":"53","author":"Scott","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102788_bib10","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/db11-0004","article-title":"NOD1 activators link innate immunity to insulin resistance","volume":"60","author":"Schertzer","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib11","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1152\/ajpendo.00181.2020","article-title":"NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice","volume":"319","author":"Cavallari","year":"2020","journal-title":"Am J Physiol Endocrinol Metabol"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib12","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3748\/wjg.v22.i8.2533","article-title":"Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation","volume":"22","author":"Sui","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2023.102788_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2021.04.008","article-title":"Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis","volume":"169","author":"Huang","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/ijms21020496","article-title":"Crosstalk between NLRP12 and JNK during hepatocellular carcinoma","volume":"21","author":"Khan","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.dsx.2023.102788_bib15","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","article-title":"Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis","volume":"70","author":"Koh","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib16","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbadis.2018.03.003","article-title":"Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome","volume":"1864","author":"Kors","year":"2018","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbrc.2017.08.017","article-title":"Dexmedetomidine (DEX) protects against hepatic ischemia\/reperfusion (I\/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice","volume":"493","author":"Chen","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.dsx.2023.102788_bib18","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/antiox11101954","article-title":"M6A RNA methylation mediates NOD1\/NF-kB signaling activation in the liver of piglets challenged with lipopolysaccharide","volume":"11","author":"Xu","year":"2022","journal-title":"Antioxidants"},{"issue":"7","key":"10.1016\/j.dsx.2023.102788_bib19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/liv.14452","article-title":"Cell-type-resolved proteomic analysis of the human liver","volume":"40","author":"\u00d6lander","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib20","first-page":"49","article-title":"Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease","volume":"9","author":"Boaru","year":"2012","journal-title":"J\u00a0Inflamm"},{"key":"10.1016\/j.dsx.2023.102788_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40396","article-title":"NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte","volume":"8","author":"Udden","year":"2019","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib22","article-title":"ER stress-induced inflammasome activation contributes to hepatic inflammation and steatosis","volume":"7","author":"Zhang","year":"2016","journal-title":"J\u00a0Clin Cell Immunol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3892\/ijmm.2017.2997","article-title":"Grape seed proanthocyanidin inhibits inflammatory responses in hepatic stellate cells by modulating the MAPK, Akt and NF-\u03baB signaling pathways","volume":"40","author":"Lee","year":"2017","journal-title":"Int J Mol Med"},{"issue":"24","key":"10.1016\/j.dsx.2023.102788_bib24","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3748\/wjg.v25.i24.3044","article-title":"Effect of NLRC5 on activation and reversion of hepatic stellate cells by regulating the nuclear factor-\u03baB signaling pathway","volume":"25","author":"Zhang","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.dsx.2023.102788_bib25","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1007\/s11033-021-06774-3","article-title":"RNA sequencing of LX-2 cells treated with TGF-\u03b21 identifies genes associated with hepatic stellate cell activation","volume":"48","author":"Carson","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.dsx.2023.102788_bib26","article-title":"Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: therapeutic potential for liver fibrosis","author":"Charan","year":"2022","journal-title":"Genes Dis"},{"key":"10.1016\/j.dsx.2023.102788_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.phrs.2016.11.040","article-title":"Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation","volume":"117","author":"Jiang","year":"2017","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11010-022-04369-5","article-title":"TGF-\u03b2 activates NLRP3 inflammasome by an autocrine production of TGF-\u03b2 in LX-2 human hepatic stellate cells","volume":"477","author":"Kang","year":"2022","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/atm.2020.02.21","article-title":"Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-\u03baB signal pathway in hepatic stellate cells","volume":"8","author":"Dong","year":"2020","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.yexcr.2018.06.040","article-title":"Effects of NLRP6 on the proliferation and activation of human hepatic stellate cells","volume":"370","author":"Zhu","year":"2018","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69295-2","article-title":"NOD1 deficiency promotes an imbalance of thyroid hormones and microbiota homeostasis in mice fed high fat diet","volume":"10","author":"Gonz\u00e1lez-Ramos","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.dsx.2023.102788_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/DMSO.S206558","article-title":"Novel role of NLRP3-inflammasome in regulation of lipogenesis in fasting-induced hepatic steatosis","volume":"12","author":"Liu","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jat.4258","article-title":"PFOS facilitates liver inflammation and steatosis: an involvement of NLRP3 inflammasome-mediated hepatocyte pyroptosis","volume":"42","author":"Qin","year":"2022","journal-title":"J\u00a0Appl Toxicol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102788_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41374-018-0177-6","article-title":"Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab Invest"},{"issue":"11","key":"10.1016\/j.dsx.2023.102788_bib35","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.celrep.2018.07.068","article-title":"FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury","volume":"24","author":"Han","year":"2018","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.dsx.2023.102788_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J\u00a0Mol Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jcmgh.2021.12.002","article-title":"Sphingosine 1-phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome","volume":"13","author":"Hong","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.32320","article-title":"NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH","volume":"76","author":"Calcagno","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.dsx.2023.102788_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41374-021-00626-1","article-title":"Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH","volume":"101","author":"Bala","year":"2021","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.30252","article-title":"NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice","volume":"69","author":"Inzaugarat","year":"2019","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.dsx.2023.102788_bib41","doi-asserted-by":"crossref","first-page":"12177","DOI":"10.18632\/aging.102559","article-title":"Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress","volume":"11","author":"Zilu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41374-021-00535-3","article-title":"NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water","volume":"101","author":"Zhu","year":"2021","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib44","article-title":"Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD","volume":"7","author":"Pierantonelli","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bbrc.2019.02.099","article-title":"NLRC4 inflammasome activation regulated by TNF-\u03b1 promotes inflammatory responses in nonalcoholic fatty liver disease","volume":"511","author":"Chen","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.dsx.2023.102788_bib46","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","article-title":"Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis","volume":"70","author":"Koh","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2023.102788_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2016.01.012","article-title":"Role of NLRC5 in progression and reversal of hepatic fibrosis","volume":"294","author":"Liu","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"issue":"24","key":"10.1016\/j.dsx.2023.102788_bib48","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3748\/wjg.v25.i24.3044","article-title":"Effect of NLRC5 on activation and reversion of hepatic stellate cells by regulating the nuclear factor-\u03baB signaling pathway","volume":"25","author":"Zhang","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2023.102788_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2021.04.008","article-title":"Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis","volume":"169","author":"Huang","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.yexcr.2018.06.040","article-title":"Effects of NLRP6 on the proliferation and activation of human hepatic stellate cells","volume":"370","author":"Zhu","year":"2018","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.dsx.2023.102788_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105740","article-title":"NLRP6 deficiency aggravates liver injury after allogeneic hematopoietic stem cell transplantation","volume":"74","author":"Li","year":"2019","journal-title":"Int Immunopharm"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00109-019-01868-9","article-title":"NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma","volume":"98","author":"Ma","year":"2020","journal-title":"J\u00a0Mol Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41419-020-2368-5","article-title":"NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.dsx.2023.102788_bib55","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3390\/ijms19113419","article-title":"Evodiamine induces apoptosis in SMMC-7721 and HepG2 cells by suppressing NOD1 signal pathway","volume":"19","author":"Guo","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-020-01028-4","article-title":"Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism","volume":"14","author":"Zhou","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102788_bib57","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/cam4.1202","article-title":"NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma","volume":"6","author":"Wang","year":"2017","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.dsx.2023.102788_bib58","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/labinvest.2015.63","article-title":"Estrogen suppresses hepatocellular carcinoma cells through Er\u03b2-mediated upregulation of the NLRP3 inflammasome","volume":"95","author":"Wei","year":"2015","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib59","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s43440-020-00064-8","article-title":"Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis","volume":"72","author":"Zhang","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.dsx.2023.102788_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbrc.2021.10.041","article-title":"FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPAR\u03b3\/NF-\u03baB\/NLRP3 pathway","volume":"582","author":"Liu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089961","article-title":"Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2023.102788_bib62","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.2147\/OTT.S260793","article-title":"Downregulation of IRAK1 prevents the malignant behavior of hepatocellular carcinoma cells by blocking activation of the MAPKs\/NLRP3\/IL-1\u03b2 pathway","volume":"13","author":"Chen","year":"2020","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2016.03.006","article-title":"NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt\/\u03b2-catenin signaling pathway","volume":"376","author":"Peng","year":"2016","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.dsx.2023.102788_bib64","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.21037\/tcr.2020.02.81","article-title":"NLRC5, a valuable marker for the diagnosis and prognostic assessment of hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-018-0573-9","article-title":"NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells","volume":"11","author":"Hu","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.dsx.2023.102788_bib66","article-title":"A\u00a0novel pyroptosis risk model composed of NLRP6 effectively predicts the prognosis of hepatocellular carcinoma patients","author":"Gao","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib67","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib68","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/ijms21020496","article-title":"Crosstalk between NLRP12 and JNK during hepatocellular carcinoma","volume":"21","author":"Khan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2023.102788_bib69","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40396","article-title":"NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte","volume":"8","author":"Udden","year":"2019","journal-title":"Elife"},{"issue":"27","key":"10.1016\/j.dsx.2023.102788_bib70","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review","volume":"22","author":"Golabi","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102788_bib71","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of nonalcoholic fatty liver disease: role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41374-020-00508-y","article-title":"Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin","volume":"101","author":"Yang","year":"2021","journal-title":"Lab Invest"},{"key":"10.1016\/j.dsx.2023.102788_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies","volume":"20","author":"Hayat","year":"2021","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib74","doi-asserted-by":"crossref","first-page":"G488","DOI":"10.1152\/ajpgi.00179.2022","article-title":"Coffee modulates insulin-HNF-4\u03b1-Cyp7b1 pathway and reduces oxysterol driven liver toxicity in a NAFLD mouse model","volume":"323","author":"Kakiyama","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"13","key":"10.1016\/j.dsx.2023.102788_bib75","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1039\/D2FO00081D","article-title":"Coffee peel extracts ameliorate non-alcoholic fatty liver disease via a fibroblast growth factor 21-adiponectin signaling pathway","volume":"13","author":"Fan","year":"2022","journal-title":"Food Funct"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100671","article-title":"Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-\u03b2\/Smad3 signaling pathways","volume":"27","author":"Vargas-Pozada","year":"2022","journal-title":"Ann Hepatol"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib77","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.7150\/ijbs.34211","article-title":"Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK\/NF-\u03baB and A2aR signaling in LPS-induced THP-1 macrophages","volume":"15","author":"Zhao","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"17","key":"10.1016\/j.dsx.2023.102788_bib78","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.3390\/ijms23179954","article-title":"Caffeine inhibits NLRP3 inflammasome activation by downregulating TLR4\/MAPK\/NF-\u03baB signaling pathway in an experimental NASH model","volume":"23","author":"Vargas-Pozada","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01663-y","article-title":"A\u00a0meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087488","article-title":"Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease","volume":"9","author":"Bernsmeier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2023.102788_bib81","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.2147\/DDDT.S224688","article-title":"Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways","volume":"13","author":"Luo","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib82","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","article-title":"Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet","volume":"505","author":"Zhu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbrc.2018.03.142","article-title":"Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1\/NOX4\/ROS pathway in H9c2 cells","volume":"499","author":"Chen","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.dsx.2023.102788_bib84","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41374-018-0177-6","article-title":"Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab Invest"},{"key":"10.1016\/j.dsx.2023.102788_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dsx.2023.102788_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1864307","article-title":"Exenatide delays the progression of nonalcoholic fatty liver disease in C57bl\/6 mice, which may involve inhibition of the NLRP3 inflammasome through the mitophagy pathway","volume":"2018","author":"Shao","year":"2018","journal-title":"Gastroenterol Res Pract"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib87","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.dsx.2023.102788_bib88","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102788_bib89","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000045","article-title":"Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1\/2 pathway","volume":"7","author":"Huang","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/a-1970-3388","article-title":"Dapagliflozin presented nonalcoholic fatty liver through metabolite extraction and AMPK\/NLRP3 signaling pathway","volume":"55","author":"Lin","year":"2023","journal-title":"Horm Metab Res"},{"issue":"10215","key":"10.1016\/j.dsx.2023.102788_bib91","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib92","first-page":"8119","article-title":"Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation","volume":"10","author":"Yang","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.dsx.2023.102788_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A\u00a0new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2023.102788_bib94","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2020.11.009","article-title":"NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice","volume":"534","author":"Wang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.dsx.2023.102788_bib95","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s11695-020-04571-8","article-title":"Sleeve gastroplasty combined with the NLRP3 inflammasome inhibitor CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis in mouse model","volume":"30","author":"Sun","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.dsx.2023.102788_bib96","article-title":"A\u00a0pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.dsx.2023.102788_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.715765","article-title":"The specific NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in experimental murine non-alcoholic steatohepatitis","volume":"8","author":"Torres","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib98","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dsx.2023.102788_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107660","article-title":"Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis","volume":"96","author":"Zhu","year":"2021","journal-title":"Int Immunopharm"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134601","article-title":"Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90","volume":"6","author":"Xu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.dsx.2023.102788_bib101","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphar.2020.00185","article-title":"Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS\/TXNIP Axis","volume":"11","author":"Mai","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dsx.2023.102788_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119778","article-title":"Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice","volume":"281","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.dsx.2023.102788_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175270","article-title":"Baicalin improved hepatic injury of NASH by regulating NRF2\/HO-1\/NRLP3 pathway","volume":"934","author":"Shi","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dsx.2023.102788_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175291","article-title":"Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation","volume":"933","author":"Zhang","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.dsx.2023.102788_bib105","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1007\/s12035-020-02071-5","article-title":"Nobiletin ameliorates NLRP3 inflammasome-mediated inflammation through promoting autophagy via the AMPK pathway","volume":"57","author":"Wang","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.dsx.2023.102788_bib106","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/JIR.S343236","article-title":"Melatonin suppresses NLRP3 inflammasome activation via TLR4\/NF-\u03baB and P2X7R signaling in high-fat diet-induced murine NASH model","volume":"15","author":"Saha","year":"2022","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.dsx.2023.102788_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.885039","article-title":"Gynostemma pentaphyllumpolysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2\/NLRP3 pathway","volume":"13","author":"Yue","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102788_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109099","article-title":"Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob\/ob mice","volume":"111","author":"Meng","year":"2022","journal-title":"Int Immunopharm"},{"issue":"1","key":"10.1016\/j.dsx.2023.102788_bib109","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-022-03495-4","article-title":"Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome","volume":"20","author":"Wu","year":"2022","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.dsx.2023.102788_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105971","article-title":"Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome","volume":"127","author":"Niu","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.dsx.2023.102788_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115405","article-title":"Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation","volume":"296","author":"Zhang","year":"2022","journal-title":"J\u00a0Ethnopharmacol"},{"issue":"19","key":"10.1016\/j.dsx.2023.102788_bib112","doi-asserted-by":"crossref","first-page":"9347","DOI":"10.1039\/D1FO01517F","article-title":"Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats","volume":"12","author":"Yang","year":"2021","journal-title":"Food Funct"},{"issue":"6","key":"10.1016\/j.dsx.2023.102788_bib113","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/md19060318","article-title":"Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis","volume":"19","author":"Oh","year":"2021","journal-title":"Mar Drugs"},{"key":"10.1016\/j.dsx.2023.102788_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111504","article-title":"4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation","volume":"138","author":"Yen","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib115","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00394-020-02305-1","article-title":"S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR\/NRF2-mediated drug metabolising enzymes and reducing NF-\u03baB\/I\u03baB\u03b1 and NLRP3\/6-mediated inflammation","volume":"60","author":"Yu","year":"2021","journal-title":"Eur J Nutr"},{"issue":"8","key":"10.1016\/j.dsx.2023.102788_bib116","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/ijms21082790","article-title":"Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2023.102788_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154241","article-title":"Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-\u03baB\/NLRP3 signaling pathway","volume":"104","author":"Deng","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.dsx.2023.102788_bib118","article-title":"Protective effects of Tiaoganquzhi decoction in treating inflammatory injury of nonalcoholic fatty liver disease by promoting CGI-58 and inhibiting expression of NLRP3 inflammasome","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dsx.2023.102788_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108126","article-title":"Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3","volume":"100","author":"Ruan","year":"2021","journal-title":"Int Immunopharm"},{"issue":"4","key":"10.1016\/j.dsx.2023.102788_bib120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s13105-018-0644-y","article-title":"Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation","volume":"74","author":"Tang","year":"2018","journal-title":"J\u00a0Physiol Biochem"},{"issue":"18","key":"10.1016\/j.dsx.2023.102788_bib121","first-page":"8158","article-title":"Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation","volume":"23","author":"Liu","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.dsx.2023.102788_bib122","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/08923973.2021.1984520","article-title":"Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress","volume":"43","author":"Li","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102788_bib123","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.joim.2021.07.004","article-title":"Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4\/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease","volume":"19","author":"Pan","year":"2021","journal-title":"J\u00a0Integr Med"},{"issue":"Pt B","key":"10.1016\/j.dsx.2023.102788_bib124","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ijbiomac.2018.09.151","article-title":"Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3\/6 pathways in a methionine choline deficient diet steatohepatitis mouse model","volume":"120","author":"Xiao","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.dsx.2023.102788_bib125","article-title":"Loganin prevents hepatic steatosis by blocking NLRP3 inflammasome activation","author":"Jang","year":"2022","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.dsx.2023.102788_bib126","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jnutbio.2019.05.015","article-title":"Apigenin ameliorates HFD-induced NAFLD through regulation of the XO\/NLRP3 pathways","volume":"71","author":"Lv","year":"2019","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.dsx.2023.102788_bib127","article-title":"Mangiferin ameliorates HFD-induced NAFLD through regulation of the AMPK and NLRP3 inflammasome signal pathways","volume":"2021","author":"Yong","year":"2021","journal-title":"J\u00a0Immunol Res"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib128","first-page":"253","article-title":"Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B\/pyrin domain-containing protein 3 pathway","volume":"40","author":"Mu","year":"2020","journal-title":"J\u00a0Tradit Chin Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102788_bib129","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1096\/fj.201700602R","article-title":"Silybin inhibits NLRP3 inflammasome assembly through the NAD(+)\/SIRT2 pathway in mice with nonalcoholic fatty liver disease","volume":"32","author":"Zhang","year":"2018","journal-title":"Faseb J"},{"issue":"4","key":"10.1016\/j.dsx.2023.102788_bib130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.bbrc.2019.12.131","article-title":"PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice","volume":"523","author":"Sun","year":"2020","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212300084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212300084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:23:10Z","timestamp":1761729790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187140212300084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":130,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S187140212300084X"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102788","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102788"}}